IPI-145 regulatory update

Infinity said FDA granted Orphan Drug designation for IPI-145 to treat follicular lymphoma. IPI-145 is in a Phase II trial to treat indolent non-Hodgkin's lymphoma (NHL), a Phase IIa trial to treat as...